FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365511221> ?p ?o ?g. }

• W4365511221 endingPage "237" @default.
• W4365511221 startingPage "237" @default.
• W4365511221 abstract "Abstract Background Most FDA-approved ADHD treatments increase norepinephrine (NE) and dopamine (DA); however, our prior preclinical studies of the non-stimulant ADHD treatment viloxazine ER (Qelbree®) demonstrated that viloxazine also increases serotonin (5-HT). A prior microdialysis study showed increases in NE, DA, and 5-HT in the rat prefrontal cortex (PFC); however, the 50 mg/kg dose resulted in supratherapeutic plasma concentrations. Viloxazine is a moderate affinity selective NE reuptake inhibitor, structurally different than traditional SSRI antidepressants. Viloxazine has negligible activity at the serotonin reuptake transporter (SERT), suggesting viloxazine has a different mechanism of 5-HT PFC elevation than SSRIs. The current microdialysis study was undertaken to further characterize if viloxazine affects 5-HT and its 5-HIAA metabolite at therapeutically relevant plasma concentrations. Results are compared to similar microdialysis studies of SSRIs. Methods Rats were implanted with I-shaped microdialysis probes connected to a microperfusion pump, delivering artificial cerebrospinal fluid, in the PFC. After a 2-hour baseline period, viloxazine (1, 3, 10, or 30 mg/kg) was administered (ip). Dialysate samples were collected from the interstitial fluid (ISF) of the PFC before and after dosing. LC-MS/MS was used to determine the dialysate concentrations of viloxazine and viloxazine-induced changes in NE, 5-HT, and their respective metabolites, DHPG and 5-HIAA. Viloxazine plasma concentrations were also measured. Animal research was approved by the Institutional Animal Care and Use Committee and conducted in accordance with the National Research Council’s Guide for the Care and Use of Laboratory Animals. Results Viloxazine administration resulted in significant dose-dependent increases in ISF NE levels and corresponding decreases in DHPG (NE metabolite) at all doses tested, reflecting viloxazine’s activity as a NET inhibitor. Viloxazine treatment also resulted in a dose-dependent elevation of ISF 5-HT levels in the PFC. Of the doses tested, 30 mg/kg was found to be clinically relevant as it induced ISF concentrations approximating unbound plasma concentrations in pediatric ADHD patients. At this dose, 5-HT levels were significantly increased over baseline and higher than vehicle levels. Coincident changes in 5-HIAA concentrations were not observed, reaffirming viloxazine’s lack of activity as a SERT inhibitor. Conclusion Viloxazine induced dose-dependent increases in NE and 5-HT in the PFC, a critical target region for ADHD therapies. At clinically relevant viloxazine plasma concentrations, 5-HT was increased in the PFC. Unlike SSRIs, which correspondingly decrease the 5-HT metabolite in the PFC (indicating serotonin reuptake inhibition), viloxazine did not affect 5-HIAA levels. Thus, viloxazine increases cortical 5-HT levels by a different mechanism than SSRIs. Whether 5-HT effects aid in viloxazine therapeutic efficacy in ADHD is yet unknown. Funding Supernus Pharmaceuticals, Inc." @default.
• W4365511221 created "2023-04-15" @default.
• W4365511221 creator A5002531863 @default.
• W4365511221 creator A5009953917 @default.
• W4365511221 creator A5033258563 @default.
• W4365511221 creator A5057463661 @default.
• W4365511221 creator A5060291858 @default.
• W4365511221 creator A5060557523 @default.
• W4365511221 date "2023-04-01" @default.
• W4365511221 modified "2023-10-17" @default.
• W4365511221 title "Viloxazine Increases Cortical Serotonin Without Inhibiting Serotonin Reuptake at Doses Used to Treat ADHD" @default.
• W4365511221 doi "https://doi.org/10.1017/s1092852923001669" @default.
• W4365511221 hasPublicationYear "2023" @default.
• W4365511221 type Work @default.
• W4365511221 citedByCount "0" @default.
• W4365511221 crossrefType "journal-article" @default.
• W4365511221 hasAuthorship W4365511221A5002531863 @default.
• W4365511221 hasAuthorship W4365511221A5009953917 @default.
• W4365511221 hasAuthorship W4365511221A5033258563 @default.
• W4365511221 hasAuthorship W4365511221A5057463661 @default.
• W4365511221 hasAuthorship W4365511221A5060291858 @default.
• W4365511221 hasAuthorship W4365511221A5060557523 @default.
• W4365511221 hasBestOaLocation W43655112211 @default.
• W4365511221 hasConcept C126322002 @default.
• W4365511221 hasConcept C170493617 @default.
• W4365511221 hasConcept C176233148 @default.
• W4365511221 hasConcept C185592680 @default.
• W4365511221 hasConcept C2775864247 @default.
• W4365511221 hasConcept C2778514916 @default.
• W4365511221 hasConcept C2780092697 @default.
• W4365511221 hasConcept C31487548 @default.
• W4365511221 hasConcept C50156730 @default.
• W4365511221 hasConcept C513476851 @default.
• W4365511221 hasConcept C71924100 @default.
• W4365511221 hasConcept C98274493 @default.
• W4365511221 hasConcept C99631742 @default.
• W4365511221 hasConceptScore W4365511221C126322002 @default.
• W4365511221 hasConceptScore W4365511221C170493617 @default.
• W4365511221 hasConceptScore W4365511221C176233148 @default.
• W4365511221 hasConceptScore W4365511221C185592680 @default.
• W4365511221 hasConceptScore W4365511221C2775864247 @default.
• W4365511221 hasConceptScore W4365511221C2778514916 @default.
• W4365511221 hasConceptScore W4365511221C2780092697 @default.
• W4365511221 hasConceptScore W4365511221C31487548 @default.
• W4365511221 hasConceptScore W4365511221C50156730 @default.
• W4365511221 hasConceptScore W4365511221C513476851 @default.
• W4365511221 hasConceptScore W4365511221C71924100 @default.
• W4365511221 hasConceptScore W4365511221C98274493 @default.
• W4365511221 hasConceptScore W4365511221C99631742 @default.
• W4365511221 hasIssue "2" @default.
• W4365511221 hasLocation W43655112211 @default.
• W4365511221 hasOpenAccess W4365511221 @default.
• W4365511221 hasPrimaryLocation W43655112211 @default.
• W4365511221 hasRelatedWork W1964309919 @default.
• W4365511221 hasRelatedWork W1967284652 @default.
• W4365511221 hasRelatedWork W1988560604 @default.
• W4365511221 hasRelatedWork W2031191336 @default.
• W4365511221 hasRelatedWork W2033735176 @default.
• W4365511221 hasRelatedWork W2055244662 @default.
• W4365511221 hasRelatedWork W2160402497 @default.
• W4365511221 hasRelatedWork W2269462376 @default.
• W4365511221 hasRelatedWork W2951988109 @default.
• W4365511221 hasRelatedWork W3095689469 @default.
• W4365511221 hasVolume "28" @default.
• W4365511221 isParatext "false" @default.
• W4365511221 isRetracted "false" @default.
• W4365511221 workType "article" @default.